Amryt Pharma
Amryt Pharma, a leading player in the pharmaceutical preparation manufacturing industry, is headquartered in Ireland (IE) and operates across various regions, focusing on innovative treatments for rare and complex diseases. Founded in 2015, the company has rapidly established itself as a key provider of specialised therapies, particularly in dermatology and metabolic disorders.
Amryt Pharma's core products, including the unique topical treatment for epidermolysis bullosa, highlight its commitment to addressing unmet medical needs. The company has achieved significant milestones, including successful product launches and strategic partnerships, positioning itself as a trusted name in the pharmaceutical landscape. With a focus on patient-centric solutions, Amryt Pharma continues to make strides in improving the quality of life for patients worldwide.
+18 vs industry average
Amryt Pharma’s score of 58 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Amryt Pharma?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2021
Reported emissions
Scope 3 accounts for ••• of total emissions.
Amryt Pharma's reported carbon emissions
Amryt Pharma, an Irish pharmaceutical preparation manufacturing company, reported total carbon emissions of approximately 368,480 kg CO2e for the year 2021. This figure represents a reduction from the approximately 441,380 kg CO2e reported in 2020.
While specific scope-level emissions data (Scope 1, 2, or 3) is not detailed in the provided information, the company's emissions data is cascaded from its corporate family. Amryt Pharma plc, the ultimate parent company for emission reporting, provides the cascaded data.
Currently, there is no publicly available information regarding Amryt Pharma's specific reduction targets, such as those validated by the Science Based Targets initiative (SBTi), or commitments to initiatives like the Climate Pledge. However, the reduction in total emissions from 2020 to 2021 suggests an ongoing effort towards environmental responsibility within its operations. The company's reporting indicates a focus on emissions per employee, with a value of approximately 1950 tonnes CO2e per employee reported for 2021, derived from their annual report.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Amryt Pharma’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Amryt Pharma yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Chiesi Farmaceutici S.p.A.
Carbon Disclosure Project
Inherited from Chiesi Farmaceutici S.p.A.The Climate Pledge
UN Global Compact Climate Champions initiative
Inherited from Chiesi Farmaceutici S.p.A.RE 100
Climate Action 100
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project